ClinicaltodayNew
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 - NEC
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 NEC
9 new development(s) in neoantigen vaccines today.
NEC Presents Phase I/II Results for Individualized Oral Neoantigen Therapy, NECVAX-NEO1 at ESMO 2026 NEC
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions. This super composite rating is th…
LG Chem plans to begin clinical development of a personalized cancer vaccine in 2029 as it expands the use of artificial intelligence from drug discovery to selecting patients most likely to benefit from treatment, aiming to improve the success rate of clinical trials. The South …
Relevant work from earlier we're still surfacing — not today's news.